Just 1 in 4 MSME pharma units set for GMP transition as deadline nears | Current Affairs | Vision IAS
MENU
Home

Periodically curated articles and updates on national and international developments relevant for UPSC Civil Services Examination.

Quick Links

High-quality MCQs and Mains Answer Writing to sharpen skills and reinforce learning every day.

Watch explainer and thematic concept-building videos under initiatives like Deep Dive, Master Classes, etc., on important UPSC topics.

ESC

Daily News Summary

Get concise and efficient summaries of key articles from prominent newspapers. Our daily news digest ensures quick reading and easy understanding, helping you stay informed about important events and developments without spending hours going through full articles. Perfect for focused and timely updates.

News Summary

Sun Mon Tue Wed Thu Fri Sat

Just 1 in 4 MSME pharma units set for GMP transition as deadline nears

26 Dec 2025
2 min

Overview of Revised GMP Norms for MSME Pharmaceutical Manufacturers

Approximately 1,700, or 26%, of India's estimated 6,500 MSME pharmaceutical manufacturers are likely to meet the revised Good Manufacturing Practices (GMP) norms by December 31. This is a requirement under the updated Schedule M norms of the Drugs and Cosmetics Act, first notified in 2022.

Compliance and Risk of Shutdowns

  • India has around 10,500 pharmaceutical manufacturing units, with nearly 8,500 under the MSME category.
  • About 2,000 MSME units already hold WHO-GMP certification, implying around 3,700 units are expected to comply with the revised norms.
  • Non-compliant units risk shutdown once inspections begin, although closures are unlikely to affect domestic drug supply significantly.

Geographical Variations in Compliance

  • States like Gujarat and Maharashtra lead in compliance, with Gujarat achieving a 98.8% submission rate for gap analysis.
  • Himachal Pradesh lags, with only 116 of over 650 units initiating the upgradation process.

Challenges and Extension for MSMEs

  • Micro and small pharma firms with turnover less than ₹250 crore were granted a compliance extension until December 31, 2025, contingent on gap analysis and application submission by May 2025.
  • Cost of compliance upgrades ranges from ₹50 lakh to ₹2.5 crore, posing capital challenges for smaller players.
  • Only 180 units applied under the government's financial incentive scheme for upgrades.

Industry Impact and Future Outlook

  • MSME units contribute about 7% to the Indian Pharma Market.
  • Potential job losses from non-compliance could be offset by the growth of GMP-certified contract manufacturing facilities.
  • Analysts suggest the government is unlikely to grant further extensions due to past incidents of non-compliance impacting public safety.

Key Statistics

  • December 31, 2025: Revised Schedule M norms compliance deadline.
  • 1,700 of 6,500 non-GMP MSME units have submitted upgrade plans.
  • 98.8% compliance in Gujarat for MSME units filing gap analysis.
  • Estimated cost of compliance upgrades: ₹50 lakh-₹2.5 crore.

Explore Related Content

Discover more articles, videos, and terms related to this topic

Title is required. Maximum 500 characters.

Search Notes

Filter Notes

Loading your notes...
Searching your notes...
Loading more notes...
You've reached the end of your notes

No notes yet

Create your first note to get started.

No notes found

Try adjusting your search criteria or clear the search.

Saving...
Saved

Please select a subject.

Referenced Articles

linked

No references added yet

Subscribe for Premium Features